ATE283487T1 - METHOD FOR DIAGNOSIS OR PROGNOSIS OF AGE-RELATED MACULAR DEGENERATION - Google Patents

METHOD FOR DIAGNOSIS OR PROGNOSIS OF AGE-RELATED MACULAR DEGENERATION

Info

Publication number
ATE283487T1
ATE283487T1 AT00967639T AT00967639T ATE283487T1 AT E283487 T1 ATE283487 T1 AT E283487T1 AT 00967639 T AT00967639 T AT 00967639T AT 00967639 T AT00967639 T AT 00967639T AT E283487 T1 ATE283487 T1 AT E283487T1
Authority
AT
Austria
Prior art keywords
age
macular degeneration
related macular
subject
activity
Prior art date
Application number
AT00967639T
Other languages
German (de)
Inventor
Richard Giesbert
Roger Nitsch
Original Assignee
Evotec Neurosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh filed Critical Evotec Neurosciences Gmbh
Application granted granted Critical
Publication of ATE283487T1 publication Critical patent/ATE283487T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

A method for diagnosing or prognosticating age-related macular degeneration in a subject, or determining whether a subject is at increased risk of developing age-related macular degeneration or monitoring the progression of age-related macular degeneration in a subject, comprising: determining a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of a transcription product of a Cystatin C gene, a translation product of a Cystatin C gene, a fragment of said translation product, an amyloid protein, and a transcription product of a gene coding for an amyloid protein in a sample from said subject; and comparing said level, or said activity, or both said level and said activity, of at least one of said substances to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said age-related macular degeneration in said subject, or determining whether said subject is at increased risk of developing age-related macular degeneration or monitoring the progression of said age-related macular degeneration in said subject.
AT00967639T 1999-09-01 2000-09-01 METHOD FOR DIAGNOSIS OR PROGNOSIS OF AGE-RELATED MACULAR DEGENERATION ATE283487T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99117198 1999-09-01
EP00101921 2000-02-01
PCT/EP2000/008554 WO2001016364A2 (en) 1999-09-01 2000-09-01 Methods of diagnosing or prognosticating age-related macular degeneration

Publications (1)

Publication Number Publication Date
ATE283487T1 true ATE283487T1 (en) 2004-12-15

Family

ID=26070484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00967639T ATE283487T1 (en) 1999-09-01 2000-09-01 METHOD FOR DIAGNOSIS OR PROGNOSIS OF AGE-RELATED MACULAR DEGENERATION

Country Status (5)

Country Link
US (1) US20070117122A1 (en)
EP (1) EP1210464B1 (en)
AT (1) ATE283487T1 (en)
DE (1) DE60016242T2 (en)
WO (1) WO2001016364A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP1861511A4 (en) * 2005-03-04 2010-01-20 Univ Duke Genetic variants increase the risk of age-related macular degeneration
KR101354876B1 (en) * 2005-06-08 2014-02-18 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 SUSCEPTIBILITY GENES FOR AGE-RELATED MACULOPATHY(ARM) ON CHROMOSOME 10q26
CA2627686A1 (en) * 2005-11-02 2007-05-18 The Government Of The United States Of America, As Represented By The Se Cretary Of Health And Human Services Method evolved for recognition and testing of age related macular degeneration (mert-armd)
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2008110283A2 (en) * 2007-03-14 2008-09-18 Dsm Ip Assets B.V. Method for prevention of age-related macular degeneration (amd)
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
EP2205631B1 (en) * 2007-10-05 2016-11-23 Genentech, Inc. Methods and compositions for diagnosis and treatment of amyloidosis
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CN103179981B (en) 2010-07-30 2017-02-08 Ac免疫有限公司 Safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2497490A1 (en) * 2011-03-07 2012-09-12 Bioquanta Methods for diagnosing and/or treating sterility
JP5721150B2 (en) * 2013-03-14 2015-05-20 学校法人 埼玉医科大学 Prediction risk of age-related macular degeneration
EP4311574A1 (en) * 2022-07-29 2024-01-31 Chung-Ang University Industry-Academic Cooperation Prevention and treatment of age-related macular degeneration through suppression of cathepsin s expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3724581A1 (en) * 1987-07-24 1989-02-02 Gruenenthal Gmbh DNA SEQUENCES COATING FOR PROTEINS WITH THE BIOLOGICAL PROPERTIES OF CYSTATINE C, PREPARATION OF THESE DNA SEQUENCES, EXPRESSION OF CYSTATINE C, AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
EP0527823A1 (en) * 1990-04-24 1993-02-24 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation

Also Published As

Publication number Publication date
EP1210464B1 (en) 2004-11-24
WO2001016364A3 (en) 2002-03-14
DE60016242D1 (en) 2004-12-30
WO2001016364A2 (en) 2001-03-08
US20070117122A1 (en) 2007-05-24
DE60016242T2 (en) 2005-12-01
EP1210464A2 (en) 2002-06-05

Similar Documents

Publication Publication Date Title
ATE283487T1 (en) METHOD FOR DIAGNOSIS OR PROGNOSIS OF AGE-RELATED MACULAR DEGENERATION
DE60233485D1 (en) METHOD FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE LOSS
Crist et al. Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer’s disease
ATE312946T1 (en) METHOD AND DEVICE FOR DETERMINING THE TISSUE SPECIFICITY OF FREE DNA IN BODY FLUID
DE60239470D1 (en) METHOD FOR EVALUATING PATHOLOGICAL ILLICIT STATES USING EXTRACELLULAR RNA
ATE419390T1 (en) METHOD FOR DIAGNOSIS OF PANCREATIC CANCER
NO20050186D0 (en) Oligosaccharide Biomarkers for Mucopolysaccharides and Other Related Disorders
RU2008103988A (en) METHOD FOR DIAGNOSIS OF MULTIPLE SCLEROSIS
ATE514948T1 (en) IN VITRO METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES
ATE474227T1 (en) DETERMINATION OF FELINE AND CANINE PROBNP
WO2017106363A1 (en) Refining diagnosis and treatment of complex multi-symptom neurological disorders
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
Klee et al. Analytic bias specifications based on the analysis of effects on performance of medical guidelines
ATE286253T1 (en) METHODS FOR DIAGNOSIS OR PROGNOSIS OF ALZHEIMER'S DISEASE
ATE494556T1 (en) METHOD FOR DIAGNOSING INFLAMMATORY DISEASES AND INFECTIONS USING LASP-1/LAP-1 DETERMINATION
DE60038614D1 (en) METHOD FOR THE DIAGNOSIS OF SYNOVIAL OR OSTEOARTICULAR DISEASES
ATE225405T1 (en) METHOD FOR DIAGNOSIS OR PROGNOSIS OF ALZHEIMER'S DISEASE: THERAPEUTIC COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE
DE60033646D1 (en) METHODS FOR DIAGNOSIS OR TREATMENT OF ALZHEIMER DISEASE
ATE343793T1 (en) METHOD FOR DIAGNOSIS, PROGNOSIS OR EVALUATION OF TREATMENT OF DEPRESSION BASED ON INCREASED NEUROTROPHIN CONCENTRATIONS IN CEREBROSPINAL FLUID.
DE502004012230D1 (en) METHOD FOR THE DIAGNOSIS OF ILLNESSES DETERMINED BY APOLIPOPROTEIN C-I
ATE485515T1 (en) METHOD FOR DIAGNOSIS OF A PERSON WITH MULTIPLE SCLERosis
ATE312914T1 (en) RDGB PROTEINS
Delacourte et al. The Biochemical Spreading of Tau and Amyloid-Precursor Protein Pathologies in Aging and Sporadic Alzheimer’s Disease
DE602005023973D1 (en) METHOD FOR THE DIAGNOSIS OF CHRONIC STRESS AND RELATED DISEASES
ATE442456T1 (en) METHOD FOR DETERMINING CIRCULATIVE DNA IN PLASMA AND DETECTING CANCER

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1210464

Country of ref document: EP

REN Ceased due to non-payment of the annual fee